Warfarin treatment during pregnancy: a clinical note

Area of Science:

• Cardiology
• Obstetrics
• Pharmacology

Background:

• Management of anticoagulation in pregnant women with mechanical heart valves is critical.
• Warfarin is teratogenic and poses risks during pregnancy, especially in the first trimester.
• Mitral valve replacement necessitates long-term anticoagulation therapy.

Observation:

• A 38-year-old woman with a mechanical mitral valve replacement was treated with warfarin.
• During the first trimester, her prothrombin time was 20% of normal.
• Anticoagulation was maintained at 40% until the 38th week of gestation.

Findings:

• The patient's anticoagulation was adjusted throughout her pregnancy.
• Heparin was administered in the final weeks leading up to delivery.
• A healthy infant was delivered without complications related to anticoagulation therapy.

Implications:

• This case highlights the successful management of warfarin and heparin anticoagulation during pregnancy.
• It demonstrates a viable strategy for pregnant women with mechanical heart valves.
• Safe delivery of a healthy infant is achievable with careful monitoring and therapeutic adjustments.